Capital Group Private Client Services, Inc. Vertex Pharmaceuticals Inc Transaction History

Capital Group Private Client Services, Inc.

$9.94 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $13.4 Million - $16.7 Million	-57,226 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $13,285 - $15,658	60 Added 0.1%	57,226 $14.9 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $879,916 - $1.11 Million	-4,971 Reduced 8.0%	57,166 $12.6 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $11.3 Million - $12.6 Million	62,137 New	62,137 $11.3 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.1 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.4 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.61 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.33 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.06 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Group Private Client Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital Group Private Client Services, Inc. with notifications on news.

Account